Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ironwood Pharmaceuticals (IRWD)
:IRWD
Holding IRWD?
Track your performance easily
IRWD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.06 - $15.70
Previous CloseN/A
Volume359.32K
Average Volume (3M)2.36M
Market Cap
$604.91M
Enterprise Value$1.19B
Total Cash (Recent Filing)$305.22M
Total Debt (Recent Filing)$366.57M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Feb 13, 2025EPS Estimate
0.06Last Dividend Ex-Date
Apr 02, 2019Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding160,028,380
10 Day Avg. Volume2,037,788
30 Day Avg. Volume2,359,266
Standard Deviation0.11
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.55
Price to Cash Flow (P/CF)14.80
P/FCF Ratio14.80
Enterprise Value/Market Cap1.96
Enterprise Value/Revenue3.14
Enterprise Value/Gross Profit0.76
Enterprise Value/Ebitda12.85
Forecast
1Y Price Target
$15.67Price Target Upside328.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Ironwood Pharma News
PremiumCompany Announcements
Ironwood Pharmaceuticals Reports Q3 2024 Performance
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageIRWD's apraglutide aims to be an improved version of the approved GLP-2 analog in SBS by providing a once-weekly vs. daily injection option and improved safety.
Market PotentialApraglutide is expected to be approved broadly as a once-weekly option in a potentially larger-than-expected market.
Regulatory OutlookThere is a high likelihood of first cycle approval for Apraglutide as one successful Phase 3 trial is typically sufficient for FDA approval.
Bears Say
EarningsLinzess sales grew 8% Q/Q but were down ~19% Y/Y due to ongoing Medicare pricing headwinds.
Financial PerformanceThe commercial stage asset Linzess, which faces eroding commercial fundamentals, and the company's high debt load outweigh the positive competitive readthrough.
Product PerformanceThe trial did not achieve the bull case of showing a statistically significant benefit on the CIC ≥1 day off PS and enteral autonomy secondary endpoints.
---
Ownership Overview
12.83% Insiders
18.96% Mutual Funds
0.42% Other Institutional Investors
32.83% Public Companies and Individual Investors
IRWD FAQ
What was Ironwood Pharmaceuticals’s price range in the past 12 months?
Ironwood Pharmaceuticals lowest stock price was $3.06 and its highest was $15.70 in the past 12 months.
What is Ironwood Pharmaceuticals’s market cap?
Ironwood Pharmaceuticals’s market cap is $604.91M.
When is Ironwood Pharmaceuticals’s upcoming earnings report date?
Ironwood Pharmaceuticals’s upcoming earnings report date is Feb 13, 2025 which is in 22 days.
How were Ironwood Pharmaceuticals’s earnings last quarter?
Ironwood Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.072 by -$0.052.
Is Ironwood Pharmaceuticals overvalued?
According to Wall Street analysts Ironwood Pharmaceuticals’s price is currently Undervalued.
Does Ironwood Pharmaceuticals pay dividends?
Ironwood Pharmaceuticals pays a Notavailable dividend of $2.285 which represents an annual dividend yield of N/A. See more information on Ironwood Pharmaceuticals dividends here
What is Ironwood Pharmaceuticals’s EPS estimate?
Ironwood Pharmaceuticals’s EPS estimate is 0.06.
How many shares outstanding does Ironwood Pharmaceuticals have?
Ironwood Pharmaceuticals has 160,028,380 shares outstanding.
What happened to Ironwood Pharmaceuticals’s price movement after its last earnings report?
Ironwood Pharmaceuticals reported an EPS of $0.02 in its last earnings report, missing expectations of $0.072. Following the earnings report the stock price went down -7.54%.
Which hedge fund is a major shareholder of Ironwood Pharmaceuticals?
Currently, no hedge funds are holding shares in IRWD
---
Ironwood Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.67 (328.14% Upside)
$15.67 (328.14% Upside)
Blogger Sentiment
Bearish
IRWD Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 933.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $44.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.6%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.38%
12-Months-Change
Fundamentals
Return on Equity
-8.02%
Trailing 12-Months
Asset Growth
-25.67%
Trailing 12-Months
Company Description
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.
---
IRWD Company Deck
---
IRWD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted robust prescription growth for LINZESS and significant progress with apraglutide, indicating a strong market position and potential for future growth. However, considerable pricing pressures on LINZESS and program adjustments in the pipeline present notable challenges.Read More>---
IRWD Stock 12 Month Forecast
Average Price Target
$15.67
▲(328.14% Upside)
Technical Analysis
Axsome Therapeutics
―
Ligand Pharma
―
Amarin
―
Collegium Pharmaceutical
―
RedHill Biopharma
―
MannKind
―
Best Analysts Covering IRWD
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-36.10%
assigned a buy rating last month
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -36.10% per trade.
---